Physician profile
Jenna Whitehead
NPI 1891452439
$4,334.00
in general payments reported to CMS, 2019-2025
28 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,517 · 2023: $1,248 · 2024: $884 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $720.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $712.89 | 2022-2025 | Breztri, Farxiga |
| Amgen INC. | $488.63 | 2022-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $452.27 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $250.50 | 2022 | |
| Optinose US, INC. | $234.70 | 2022-2025 | |
| Dexcom, INC. | $218.93 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $197.22 | 2024-2025 | |
| Novo Nordisk INC | $187.56 | 2022-2025 | Rybelsus, Wegovy, Ozempic |
| Abbott Laboratories | $118.06 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $108.05 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $99.01 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.70 | 2022-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $82.70 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.81 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.54 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.98 | 2022 | |
| Mylan Specialty L.P. | $30.82 | 2022 | |
| Sanofi Pasteur INC. | $27.59 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.59 | 2022 | |
| Bioxcel Therapeutics, INC. | $17.94 | 2023 | Igalmi |
| Xeris Pharmaceuticals, INC. | $17.12 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $16.53 | 2023 | Nuedexta |
| Idorsia Pharmaceuticals US INC | $16.41 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $15.80 | 2022 | |
| Organon LLC | $15.80 | 2025 | Nexplanon |
| Nestle Healthcare Nutrition INC. | $13.68 | 2022 | |
| Amarin Pharma, INC. | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.